Navigation Links
MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Date:11/21/2011

DALLAS, Texas, November 21, 2011 /PRNewswire/ --

The report "Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in North America, & Europe.

Browse market data tables and in-depth TOC on Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 - 2020).
http://www.marketsandmarkets.com/Market-Reports/chronic-lymphocytic-leukemia-223.html
Early buyers will receive 10% customization on reports.

Leukemia is the cancer of the white blood cells or the bone marrow, which occurs due to an abnormal increase in the count of white blood cells. It is identified by the spread of the diseases (either acute or chronic), and by the type of the blood cell that is affected (lymphocytic or myelocytic). This type of cancer can again be categorized into acute lymphoblastic leukemia (ALL), which accounts for about 12%, chronic lymphocytic leukemia (CLL) which accounts for 35%, acute myelogenous leukemia (AML) which accounts for 29%, and chronic myelogenous leukemia (CML) which accounts for 11% of the total leukemia.

The leukemia therapeutics market [ http://www.marketsandmarkets.com/Market-Reports/chronic-lymphocytic-leukemia-223.html ] was valued at $6.3 billion in 2010 and is expected to reach $11.3 billion by 2020 at a CAGR of 3.84% between 2015 and 2020. The market was dominated by chronic myeloid leukemia in 2010. However, in 2020, the market is expected to be equally dominated by acute lymphocytic leukemia and chronic myeloid leukemia, with sales amounting to $3.91 billion and $3.58 billion respectively.

According to WHO, leukemia is expected to be more prominent in the developed world such as North America and European countries due to genetic factor. The other causes such as environmental factor and radiation exposure are also the causative factors of all the types of leukemia.

The U.S. dominates the leukemia drug market in North America with 62% share; whereas Germany dominates the market of Europe with 31.05% share.

The major players in the market include F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline Pharmaceuticals Limited (U.K.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Eisai Co. Ltd (Japan), Biogen Idec (U.S.), ERYtech Pharma (France) Celgene Corporation (U.S.), Genmab A/S (Denmark), Cephalon Inc. (U.S.), Clavis Pharma (Norway), and Pfizer Inc. (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.

Contact:
Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/
http://twitter.com/marketsmarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
2. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
3. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015
4. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014
5. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
6. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
7. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014
8. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
9. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
10. The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority
11. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):